Articles - Articles
- Press Release: Publication of EAPM Special Issue on 'Access for All: A Personalised Approach'
Brussels, June 7th, 2016: In December of last year, during the Luxembourg Presidency of the EU, the European Council issued its conclusions on personalised medicine for patients, highlighting how ‘the development of personalised medicine may offer new opportunities for the treatment of patients in the European Union.
- Stakeholders Update: Genomics and its potential for personalised medicine
The Brussels-based European Alliance for Personalised Medicine (EAPM) this week hosted a high-level meeting to "Share views and opportunities for an European level initiative on genomics". Leading experts in the field gathered in the Belgian capital on 31 May to discuss a framework necessary to support an environment for personalised medicine. The aim was also to obtain multi-stakeholder consensus via bottom-up policy-making to support EU Member States and the European Commission.
- #Brexit and #health: What departure may mean
The in-out referendum in the UK on EU membership is getting close, now, with just a few weeks for those undecided citizens to make up their minds. Britain joined what as then the EEC in 1973 (voting to stay in two years later) and, today, has 73 European Parliament seats (one less than France and 23 less than Germany, both of whom have bigger populations) pus 29 Council votes (joint equal highest with France, Germany and Italy), writes European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan.
- Personalised medicine group helps shape new IVD rules
The European Parliament and European Council have reached a political agreement on the Medical Device Regulation and the In Vitro Medical Device Regulation. The discussions have been ongoing since 2012. The Brussels-based European Alliance for Personalised Medicine (EAPM) welcomes the inclusion of many suggestions and recommendations it has made during the process, writes European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan.
- Genetic testing not yet perfect - but it’s benefits are realIn this fast-moving world of science, especially in medicine, genetic testing is seen by many to have a high potential value.
Over in the United States, President Obama began a $215 million precision medicine initiative early in 2015, defined it as an approach that accounts for “individual differences in people’s genes, environments and lifestyles”.
- Press Release: Top-level conference ‘takes stock’ of personalised medicine
Brussels, 4 April: The theme of the European Alliance for Personalised Medicine’s fourth annual Presidency conference, during the Dutch Presidency of the EU, will be "Taking Stock: Where we are now and the necessary next steps" on April 5th/6th.
The event will bring together key decision makers and thought leaders in the exciting new arena of personalised medicine.
- Rare diseases: looking better in genes
February 28 is Rare Disease Day. The European Commission defines rare diseases as any disease affecting fewer than five people in 10,000. Its figures estimate that, today in the EU, 5-8000 distinct rare diseases affect 6-8% of the population – that’s between 27-36 million people. The EU executive adds that: “The number of patients affected by each particular rare disease is, by definition, limited. There are diseases which may affect only very few patients, in particular in smaller Member States. This, together with the fragmentation of knowledge across the EU, makes rare diseases a primary example of where working at European level is both necessary and highly beneficial.”
- Almost there: Gene technology in the health arena
Understanding of genomics has increased substantially since the year 2000, by which point the majority of the genome had been sequenced as part of the Human Genome Project. In April 2003, scientists announced that they had completed the Project, which was tasked with putting together a list of the three billion letters of genetic code that make up human DNA. (The original idea was to develop a resource - a reference genome representing humanity.)